Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Drug Proves Helpful for Treating Long-Term Insomnia

22.10.2003


Researchers at Duke University Medical Center and elsewhere have completed the first large-scale study demonstrating sustained efficacy of a medication to treat insomnia for a period of six months.



Eszopiclone (trade name Estorra), was administered nightly to patients with chronic insomnia and led to significant improvement in patients’ ability to fall asleep and stay asleep and in the quality of their sleep without any evidence of a loss of effect over time, the researchers said. Prior to this study, the longest large-scale, placebo-controlled study of a sleep medication for insomnia lasted five weeks.

The data further demonstrate that improvements in sleep were associated with consistent improvements in the patients’ ratings of their capacity to function well during the day, said the researchers. Impairments in daytime function are one aspect of chronic insomnia, and the new study represents the first time any sleep medication has been shown to consistently improve all of the components that define insomnia, they said.


Insomnia is the perception of inadequate or poor-quality sleep that is accompanied by significant distress or impaired function. It is considered to be chronic if it occurs on most nights and lasts a month or more, according to the National Institute of Health.

"I believe that this study is a milestone for research into insomnia treatments," said Andrew Krystal, M.D., lead study author and associate professor of psychiatry and director of the Sleep Research Laboratory and Insomnia Clinic at Duke. "It greatly extends the period of time that a medication has been definitively shown to help people suffering from insomnia and it establishes that studies of longer-term drug treatment of insomnia are not only feasible but can be safely performed."

The research findings appear in the Nov. 1, 2003, issue of the journal Sleep.

The researchers randomized 788 patients aged 21 to 69 into a six-month, double-blind, placebo-controlled study of three-milligram nightly doses of eszopiclone to treat their insomnia. Participants were required to meet the standard criteria used to make the clinical diagnosis of primary insomnia and to report, on average, less than six-and-a-half hours of sleep per night, or that it took at least 30 minutes to fall asleep for at least one month prior to being screened for the study.

According to Krystal, the results provide the first step toward establishing an empirical base to guide the long-term treatment of chronic insomnia with medication. The findings suggest that eszopiclone has the potential to provide doctors with a treatment option that could be prescribed for patients who require longer-term treatment. The data demonstrate that eszopiclone is safe and could be helpful. By opening the door for future studies of longer-term treatments for insomnia, this study represents an important step in the evolution toward improving treatment options for patients with chronic insomnia, he added.

"The fact that eszopiclone improved not only the difficulties in sleep that patients experience but also their reports of problems they typically experience during their waking hours, suggests the need for a change in our perspective," Krystal said. "The idea that effective treatment should address the entire spectrum of difficulties experienced by patients with insomnia is really a new way of thinking for the field."

An estimated 2.5 percent of Americans take sleep medications for insomnia in any given year, the researchers report. Of these, about 23 percent take such medications on a nightly basis for four months or longer. However, clinical research studies have examined the use of such drugs for an average use of one week. The problem with this, the researchers say, is that long-term drug treatment is being carried out without the existence of research supporting that long-term use is safe or effective in adults.

Nearly 60 percent of American adults surveyed about their sleep habits say they experience sleep problems more than a few times each week, according to the National Sleep Foundation. In their 2003 "Sleep in America" poll, the group found that insomnia is the most common sleep problem and that only one in eight older adults say their problems have been diagnosed.

Of the many people who report sleep problems, 20 to 36 percent report that their problem lasted for more than one year. Thus, the researchers say, it is not surprising that so many people are using sleep medications for long periods of time.

Research funding was supported by Sepracor, Inc., the manufacturer of eszopiclone, a compound currently under review by the Food and Drug Administration.

Krystal has previously designed and conducted other studies for Sepracor and has served on an advisory board there.

Other authors on the study include James Walsh, Ph.D., of St. John’s/St. Luke’s Hospital and St. Louis University; Eugene Laska, Ph.D., of Nathan Klein Institute for Psychiatric Research and New York University School of Medicine; Judy Caron, Ph.D., of Sepracor, Inc. in Marlborough, Mass.; and David Amato, Ph.D., Thomas Wessel, Ph.D., and Thomas Roth, Ph.D., all of Henry Ford Sleep Disorders Center in Detroit, Mich.

Tracey Koepke | dukemed news
Further information:
http://dukemednews.org/news/article.php?id=7126

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Water - as the underlying driver of the Earth’s carbon cycle

17.01.2017 | Earth Sciences

Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

17.01.2017 | Materials Sciences

Smart homes will “LISTEN” to your voice

17.01.2017 | Architecture and Construction

VideoLinks
B2B-VideoLinks
More VideoLinks >>>